Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Exelixis liver cancer results are gratifying, so do not worry if some pretend they do not like them

July 5, 2018 0

The New England Journal of Medicine (NEJM) published results from the CELESTIAL phase 3 pivotal trial …

The FDA Clears Compugen’s and Bayer’s IND Application for Their Checkpoint Inhibitor Immunotherapy Product

July 3, 2018 0

Finally, we are hearing what we were constantly expecting to hear coming out of Compugen’s (CGEN) …

Finding reasons for underperforming stocks

July 2, 2018 0

The Week in Review #25 When Stocks Plummet for No Relevant Reasons Sometimes investors need to know …

Why Vertex added over $20 to its stock price today

June 29, 2018 0

Health Canada Approves PrSYMDEKO™ For People Ages 12 and Older With Certain CFTR Gene Mutations Vertex …

The FDA approved a combination of two products. Both belong to Array Biopharma

June 28, 2018 0

The FDA approved Array BioPharma’s (ARRY) products Braftovi™ capsules in combination with Mektovi® tablets for unresectable or …

Exploring two clinical-stage firms with new, different approaches to treatments

June 27, 2018 0

SOPHIRIS BIO AND NANOBIOTIX SOPHIRIS BIO Sophiris Bio (SPHS) has a product called Topsalysin (PRX302) in …

Our outperforming firms and more

June 25, 2018 0

The Week in Review #24 Biotech Stocks’ Performances, Products on the Move and Biotech Research Biotechnology …

Incyte’s promising trial results and its plans to accelerate its future growth

June 21, 2018 0

Incyte (INCY) announced positive topline results from its pivotal Phase 2 REACH1 trial evaluating ruxolitinib (Jakafi®) …

Reasons for RegenxBio’s outperformance and some other Prohost big winners

June 20, 2018 0

On May 25, in Prohost Letter Issue #421, we wrote about RegenxBio (RGNX), which from behind …

Finally! CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences are granted the patent they have long been looking for

June 20, 2018 0

CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences, Inc., announced the news about the granted U.S. Patent No. …

Sarepta announced successful results from a preliminary trial for Duchenne Muscular Dystrophy

June 19, 2018 0

Sarepta Therapeutics (SRPT) has news from preliminary Duchenne muscular dystrophy trials. Although the number of recruited …

Good News, Bad News & Comebacks. See Also: ASCO Results

June 19, 2018 0

The Week in Review #23 ASCO 2018 - Small publicly-traded oncology biotech firms, large oncology biotech …

Why FDA approval of Agilent Technologies’ Assay is important to cervical cancer patients

June 15, 2018 0

The U.S. Food and Drug Administration (FDA) has approved Agilent Technologies’ (NYSE: A) Dako PD-L1 IHC 22C3 pharmDx …

The FDA Approves Keytruda for primary Mediastinal Large B-Cell Lymphoma (PMBCL)

June 14, 2018 0

– Keytruda becomes the first anti-PD-1 therapy to be approved for PMBCL – This is the …

CRISPR Editing and the two published studies

June 12, 2018 0

Slashing of the CRISPR gene editing companies’ stocks, including CRISPR Therapeutics (CRSP), Editas (EDIT) and Intellia (NTLA) is caused …

New stock selection and re-evaluation

June 8, 2018 0

Prohost Letter #422 SUMMARY OF THE PAST ISSUE ARTICLE - REVISITING PROMISING FIRMS (PART1) - The …

More promising news for Array from its melanoma combination clinical trial

June 5, 2018 0

Array BioPharma (ARRY) announced updated results from the Phase 3 COLUMBUS trial in BRAF-mutant advanced melanoma. The results showed …

About Nektar’s product NKTR- 214 at ASCO

June 4, 2018 0

The real news coming from the presentation at ASCO related to the combination of Nektar Therapeutics (NKTR) and Bristol-Myers Squibb …

On CRISPR Therapeutics’ news

May 31, 2018 0

CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX) announced that The U.S. Food and Drug Administration (FDA) has placed a clinical hold on …

The FDA accepted Exelixis’ supplemental new drug application of Cabometyx® for previously treated advanced Hepatocellular Carcinoma. The FDA approved Imdexxy developed by TherapeuticsMD for moderate to severe Dyspareunia

May 30, 2018 0

The U.S. Food and Drug Administration (FDA) has accepted for filing Exelixis’ (EXEL) supplemental New Drug Application (sNDA) for Cabometyx® (cabozantinib) tablets …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Exelixis liver cancer results are gratifying, so do not worry if some pretend they do not like them

The FDA Clears Compugen’s and Bayer’s IND Application for Their Checkpoint Inhibitor Immunotherapy Product

Finding reasons for underperforming stocks

Why Vertex added over $20 to its stock price today

The FDA approved a combination of two products. Both belong to Array Biopharma

Exploring two clinical-stage firms with new, different approaches to treatments

Our outperforming firms and more

Incyte’s promising trial results and its plans to accelerate its future growth

Reasons for RegenxBio’s outperformance and some other Prohost big winners

Finally! CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences are granted the patent they have long been looking for

Sarepta announced successful results from a preliminary trial for Duchenne Muscular Dystrophy

Good News, Bad News & Comebacks. See Also: ASCO Results

Why FDA approval of Agilent Technologies’ Assay is important to cervical cancer patients

The FDA Approves Keytruda for primary Mediastinal Large B-Cell Lymphoma (PMBCL)

CRISPR Editing and the two published studies

New stock selection and re-evaluation

More promising news for Array from its melanoma combination clinical trial

About Nektar’s product NKTR- 214 at ASCO

On CRISPR Therapeutics’ news

The FDA accepted Exelixis’ supplemental new drug application of Cabometyx® for previously treated advanced Hepatocellular Carcinoma. The FDA approved Imdexxy developed by TherapeuticsMD for moderate to severe Dyspareunia